AveXis (AVXS) PT Raised to $50 at Jefferies on Evidence of Trial Patient Walking

Jefferies analyst Biren Amin reiterated a Buy rating and boosted his price target on AveXis (NASDAQ: AVXS) to $50.00 (from $42.00) after they found a patient they believe is in the AVXS-101 trial whose parents posted a video of her walking.

While the firm does not have 100% confirmation that this patient is indeed in the AVXS trial, they think there's a strong likelihood that she is in the AVXS-101 trial.

"We believe her achievement to walk is significant given that she a Type 1 SMA baby w/ 2 copy number and would not in any normal circumstance be expected to walk (walking seen in Type 3 SMA). Our finding comes ahead of AVXS' plan to disclose patient data on motor milestones from its PI trial later this year."

For an analyst ratings summary and ratings history on AveXis click here. For more ratings news on AveXis click here.

Shares of AveXis closed at $41.72 yesterday.

You May Also Be Interested In

• BRF - Brasil Foods S.A. (BRFS3:BZ) (BRFS) PT Raised to BRL19 at Itau BBA
• Morgan Stanley (MS) PT Raised to $108 at CFRA
• Darling Ingredients (DAR) PT Lowered to $62 at JPMorgan